Clinical trial M18-868
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AbbVie |
EudraCT Identifier | 2021-001811-94 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04928846 |
Last update |